Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2020-09-17 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from 圣湘生物科技股份有限公司 regarding the use of temporarily idle raised funds for cash management. It details the board's approval, investment purpose, scope, risk control measures, and includes opinions from independent directors, the supervisory board, and the sponsoring institution. The document references regulatory approvals and compliance with China Securities Regulatory Commission rules. It is not a full financial report, audit report, or earnings release, but rather a disclosure about the company's capital management activities related to raised funds. The document length is 3481 characters, which is relatively short and focused on a specific financing-related update. Therefore, it fits best under Capital/Financing Update (CAP).
2020-09-17 Chinese
独立董事关于使用部分超募资金永久补充流动资金的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on the use of part of the raised funds to permanently supplement working capital. It references regulatory guidelines and the company's internal rules regarding the use of raised funds. The document is short (809 characters) and primarily consists of an opinion statement and signatures, without detailed financial data or comprehensive reporting. It is not a full financial report, audit, or management report, but rather a regulatory compliance opinion related to capital use. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2020-09-17 Chinese
关于召开2020年第二次临时股东大会的通知
Regulatory Filings Classification · 95% confidence The document is a notice about convening the 2020 second extraordinary general meeting of shareholders for 圣湘生物科技股份有限公司. It details the meeting date, voting methods, agenda items to be discussed, and procedural instructions for shareholders. It does not contain financial statements or results but is an announcement related to a shareholders' meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly a meeting notice. However, since it is a notice of the meeting and agenda rather than the voting results, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the meeting and voting procedures, not the actual voting results or the meeting materials themselves. The document length is under 5,000 characters and is primarily an announcement, not a full report or transcript.
2020-09-17 Chinese
关于使用部分超募资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the use of a portion of over-raised funds (超募资金) to permanently supplement working capital. It details the board and supervisory committee approvals, independent director opinions, and compliance with regulatory requirements. The document does not contain financial statements or detailed financial performance data but rather focuses on the company's capital usage plan and related approvals. It is a regulatory announcement about capital use rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3445 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is CAP with high confidence.
2020-09-17 Chinese
公司章程
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association for a Chinese company, covering chapters on general provisions, business scope, shares issuance and transfer, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution, audit, notices and announcements, mergers, amendments to the charter, and other related governance matters. It includes detailed provisions on shareholder rights, board and management roles, share issuance, share repurchase, and shareholder meeting procedures. There is no indication that this is an annual report, earnings release, or any financial statement. Instead, it is a governance document outlining the company's internal rules and structure. Therefore, the document fits the category of Governance Information (CGR). The document length (15,000 characters) and content confirm it is the full governance charter, not just an announcement or summary.
2020-08-26 Chinese
首次公开发行股票科创板上市公告书
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) and listing of Sansure Biotech Inc. on the Shanghai Stock Exchange's STAR Market (科创板). It includes extensive information about the company's business risks, financial data, stock issuance details, shareholder lock-up periods, and regulatory approvals from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The document is titled as a "首次公开发行股票 科创板上市公告书" which translates to "Initial Public Offering and STAR Market Listing Announcement." It is not a full annual or quarterly report, nor is it a simple announcement of a report. It is a comprehensive IPO prospectus or listing announcement document. Given the filing categories, this type of document best fits under "Regulatory Filings (RNS)" as it is a regulatory announcement related to stock issuance and listing, but not a direct financial report like a 10-K or IR. The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a certification letter. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-08-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.